Title: Risk of Clostridioides difficile infection in inflammatory bowel disease patients
undergoing vedolizumab treatment: a systematic review and meta-analysis
Version: 0 Date: 25 Jun 2024
Reviewer's report:
Dr. Chen W and colleagues complied with existing evidence without fail and conducted a meta-
analysis to examine the risk of CDI in patients with inflammatory bowel disease treated with
vedolizumab.
This study was conducted meticulously and appears to have required a great deal of effort. I
would like to extend my sincere gratitude to Dr Chen W and his colleagues.
However, some corrections are required for this paper to be accepted.
Major:
Currently, the term Clostridium difficile is not widely used, and is often written as Clostridioides
difficile. Also, it should be written in italics. I recommend that you rewrite it as above.
Minor
Regarding item "Risk of C. difficile infection in IBD patients in treatment of vedolizumab" in
the Results section, the risk of serious CDI is described as 0.20/100 person-years (95%CI 0.04
to 1.11; I2=92%), but when referring to Figure 2D, it is described as 0.586/100 person-years
(95%CI 0.220 to 1.561; I2=0%), which is inconsistent.
I recommend you check the above items.
Title: Risk of Clostridioides difficile infection in inflammatory bowel disease patients
undergoing vedolizumab treatment: a systematic review and meta-analysis
Version: 0 Date: 25 Jun 2024
Reviewer's report:
Dr. Chen W and colleagues complied with existing evidence without fail and conducted a meta-
analysis to examine the risk of CDI in patients with inflammatory bowel disease treated with
vedolizumab.
This study was conducted meticulously and appears to have required a great deal of effort. I
would like to extend my sincere gratitude to Dr Chen W and his colleagues.
However, some corrections are required for this paper to be accepted.
Major:
Currently, the term Clostridium difficile is not widely used, and is often written as Clostridioides
difficile. Also, it should be written in italics. I recommend that you rewrite it as above.
Minor
Regarding item "Risk of C. difficile infection in IBD patients in treatment of vedolizumab" in
the Results section, the risk of serious CDI is described as 0.20/100 person-years (95%CI 0.04
to 1.11; I2=92%), but when referring to Figure 2D, it is described as 0.586/100 person-years
(95%CI 0.220 to 1.561; I2=0%), which is inconsistent.
I recommend you check the above items.
Please review this paper.
user
Title: Risk of Clostridioides difficile infection in inflammatory bowel disease patients
undergoing vedolizumab treatment: a systematic review and meta-analysis
Version: 0 Date: 25 Jun 2024
Reviewer's report:
Dr. Chen W and colleagues complied with existing evidence without fail and conducted a meta-
analysis to examine the risk of CDI in patients with inflammatory bowel disease treated with
vedolizumab.
This study was conducted meticulously and appears to have required a great deal of effort. I
would like to extend my sincere gratitude to Dr Chen W and his colleagues.
However, some corrections are required for this paper to be accepted.
Major:
Currently, the term Clostridium difficile is not widely used, and is often written as Clostridioides
difficile. Also, it should be written in italics. I recommend that you rewrite it as above.
Minor
Regarding item "Risk of C. difficile infection in IBD patients in treatment of vedolizumab" in
the Results section, the risk of serious CDI is described as 0.20/100 person-years (95%CI 0.04
to 1.11; I2=92%), but when referring to Figure 2D, it is described as 0.586/100 person-years
(95%CI 0.220 to 1.561; I2=0%), which is inconsistent.
I recommend you check the above items.
assistant